Evidence map›Paper›PMID 37919726›Full record

ArticleBMC urology2023

Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry.

O Garin, C Kowalski, V Zamora, R Roth, M Ferrer, C Breidenbach, A Pont, T R Belin, D Elashoff, H Wilhalme and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 5 countries.

O GarinHealth Services Research Group, IMIM (Hospital del Mar Medical Research Institute) Barcelona Biomedical Research Park, Office 144, Doctor Aiguader 88, Barcelona, 08003, Spain.
C KowalskiGerman Cancer Society, Berlin, Germany.
V ZamoraHealth Services Research Group, IMIM (Hospital del Mar Medical Research Institute) Barcelona Biomedical Research Park, Office 144, Doctor Aiguader 88, Barcelona, 08003, Spain.
R RothInstitute of Medical Statistics and Computational Biology (IMSB), Medical Faculty, University of Cologne, Cologne, Germany.
M FerrerHealth Services Research Group, IMIM (Hospital del Mar Medical Research Institute) Barcelona Biomedical Research Park, Office 144, Doctor Aiguader 88, Barcelona, 08003, Spain. mferrer@imim.es.
C BreidenbachGerman Cancer Society, Berlin, Germany.
A PontHealth Services Research Group, IMIM (Hospital del Mar Medical Research Institute) Barcelona Biomedical Research Park, Office 144, Doctor Aiguader 88, Barcelona, 08003, Spain.
T R BelinUniversity of California, Los Angeles, USA.
D ElashoffUniversity of California, Los Angeles, USA.
H WilhalmeUniversity of California, Los Angeles, USA.
A V NguyenUniversity of California, Los Angeles, USA.
L KwanUniversity of California, Los Angeles, USA.
E K PearmanUniversity of California, Los Angeles, USA.
A BolaganiUniversity of California, Los Angeles, USA.
F SampurnoSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
N PapaSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
C MooreUniversity College London, London, UK.
J MillarSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
S E ConnorUniversity of California, Los Angeles, USA.
P VillantiMovember Foundation, Melbourne, Australia.
M S LitwinUniversity of California, Los Angeles, USA.
True North Global Registry
University of California, Los Angeles · USUniversitat Pompeu Fabra · ESGerman Cancer Society · DEMonash University · AUUniversity College London · GBBarcelona Biomedical Research Park · ESMovember Foundation · AUUniversitat Autònoma de Barcelona · ESUniversity of Cologne · DE

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR 2021 SGR 00624Instituto de Salud Carlos III CB06/02/0046Movember Foundation TrueNTH Global Registry PCO-CRV
6 · The paper itself

Abstract

introductionSimilar Patient-Reported Outcomes (PROs) at diagnosis for localized prostate cancer among countries may indicate that different treatments are recommended to the same profile of patients, regardless the context characteristics (health systems, medical schools, culture, preferences…). The aim of this study was to assess such comparison.

methodsWe analyzed the EPIC-26 results before the primary treatment of men diagnosed of localized prostate cancer from January 2017 onwards (revised data available up to September 2019), from a multicenter prospective international cohort including seven regions: Australia/New Zealand, Canada, Central Europe (Austria / Czech Republic / Germany), United Kingdom, Italy, Spain, and the United States. The EPIC-26 domain scores and pattern of three selected items were compared across regions (with Central Europe as reference). All comparisons were made stratifying by treatment: radical prostatectomy, external radiotherapy, brachytherapy, and active surveillance.

resultsThe sample included a total of 13,483 men with clinically localized or locally advanced prostate cancer. PROs showed different domain patterns before treatment across countries. The sexual domain was the most impaired, and the one with the highest dispersion within countries and with the greatest medians' differences across countries. The urinary incontinence domain, together with the bowel and hormonal domains, presented the highest scores (better outcomes) for all treatment groups, and homogeneity across regions.

conclusionsPatients with localized or locally advanced prostate cancer undergoing radical prostatectomy, EBRT, brachytherapy, or active surveillance presented mainly negligible or small differences in the EPIC-26 domains before treatment across countries. The results on urinary incontinence or bowel domains, in which almost all patients presented the best possible score, may downplay the baseline data role for evaluating treatments' effects. However, the heterogeneity within countries and the magnitude of the differences found across countries in other domains, especially sexual, support the need of implementing the PRO measurement from diagnosis.

Indexed as

BrachytherapyProstatic NeoplasmsUrinary IncontinenceHumansMaleMulticenter Studies as TopicPatient Reported Outcome MeasuresProspective StudiesProstatectomyQuality of LifeRegistriesHealth-related quality of lifePatient-reported outcomesProstate cancerRegistry

Identifiers

PMID37919726
PMCPMC10623840
OpenAlexW4388300708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.